{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T15:15:49Z","timestamp":1794323749292,"version":"4.9.0"},"reference-count":79,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The US Food and Drug Administration (FDA) recently issued a safety alert regarding cholestasis as a potential adverse reaction to immune checkpoint inhibitor (ICI) therapy. However, the underlying mechanisms of ICI-induced cholestasis remain poorly elucidated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This study analyzed adverse event reports of cancer patients treated with ICIs, extracted from the FAERS (2013\u20132023) and VigiBase (1968\u20132023) databases. The reporting odds ratio (ROR) and information component (IC) methods were employed to evaluate the association between cholestasis and ICIs therapy, while time-to-onset (TTO) analysis was conducted. Clinical data from hospitals and results from mouse experiments were integrated to validate the analysis findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Both ROR and IC analyses demonstrated a statistically significant elevation in cholestasis risk among ICI-treated patients compared to those receiving conventional chemotherapy. A heightened risk was observed in the 0\u201365 age cohort, with no significant gender-specific disparities noted. The TTO analysis revealed a delayed onset of cholestasis in both ICI-treated patients and female subjects compared to their respective counterparts. Gene expression profiling elucidated multiple cholestasis-associated signaling pathways, encompassing biliary inflammation, bile acid metabolic disorders, and impairment of hepatocellular drug metabolism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>ICI-treated patients exhibit a higher cholestasis risk compared to conventional chemotherapy. Long-term liver function monitoring is crucial for patient safety. ICI-related cholestasis may result from immune-mediated bile duct injury or metabolic disorders, potentially influenced by baseline liver function. This comprehensive article provides crucial evidence for the risk assessment and management of ICI-related cholestasis, thereby contributing to safe medication use and enhanced patient care in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000002607","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T14:00:14Z","timestamp":1749218414000},"page":"5105-5121","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Immunotherapy-induced cholestasis in cancer: insights from the two real-world pharmacovigilance databases of FAERS and VigiBase"],"prefix":"10.1097","volume":"111","author":[{"given":"Xinrong","family":"Yan","sequence":"first","affiliation":[{"name":"Department of Oncology, Zhujiang Hospital, The First School of Clinical Medicine, Southern Medical University; Donghai County People\u2019s Hospital (Affiliated Kangda College of Nanjing Medical University), Lianyungang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengrui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oral and Cranio-Maxillofacial Surgery, Shanghai Ninth People\u2019s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, and Shanghai Research Institute of Stomatology, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimin","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Urology, Changhai Hospital, Naval Medical University (Second Military Medical University), Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Zhujiang Hospital, The First School of Clinical Medicine, Southern Medical University; Donghai County People\u2019s Hospital (Affiliated Kangda College of Nanjing Medical University), Lianyungang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xufeng","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Data Visualization, Faculty of Informatics, University of Debrecen, Debrecen, Hungary"},{"name":"Faculty of Dentistry, University of Debrecen, Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"Hajdu","sequence":"additional","affiliation":[{"name":"Department of Data Visualization, Faculty of Informatics, University of Debrecen, Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hank Z.H.","family":"Wong","sequence":"additional","affiliation":[{"name":"Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Oncology, Zhujiang Hospital, The First School of Clinical Medicine, Southern Medical University; Donghai County People\u2019s Hospital (Affiliated Kangda College of Nanjing Medical University), Lianyungang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8215-2045","authenticated-orcid":false,"given":"Peng","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Zhujiang Hospital, The First School of Clinical Medicine, Southern Medical University; Donghai County People\u2019s Hospital (Affiliated Kangda College of Nanjing Medical University), Lianyungang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"R1-20261030","doi-asserted-by":"crossref","first-page":"875974","DOI":"10.3389\/fmed.2022.875974","article-title":"Overview of checkpoint inhibitors mechanism of action: role of immune-related adverse events and their treatment on progression of underlying cancer","volume":"9","author":"Iranzo","year":"2022","journal-title":"Front Med"},{"key":"R2-20261030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41419-023-06389-5","article-title":"Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks","volume":"15","author":"Meng","year":"2024","journal-title":"Cell Death Dis"},{"key":"R4-20261030","doi-asserted-by":"crossref","first-page":"378","DOI":"10.21147\/j.issn.1000-9604.2024.04.03","article-title":"SOX11 as a potential prognostic biomarker in hepatocellular carcinoma linked to immune infiltration and ferroptosis","volume":"36","author":"Chen","year":"2024","journal-title":"Chin J Cancer Res"},{"key":"R5-20261030","doi-asserted-by":"crossref","first-page":"723066","DOI":"10.3389\/fphar.2021.723066","article-title":"Glycogen metabolism predicts the efficacy of immunotherapy for urothelial carcinoma","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Pharmacol"},{"key":"R6-20261030","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2217\/imt-2022-0175","article-title":"CACNA1C mutation as a prognosis predictor of immune checkpoint inhibitor in skin cutaneous melanoma","volume":"15","author":"Huang","year":"2023","journal-title":"Immunotherapy"},{"key":"R7-20261030","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2147\/JIR.S394894","article-title":"Mutations status of NOTCH signaling pathway predict prognosis of immune checkpoint inhibitors in colorectal cancer","volume":"16","author":"Lin","year":"2023","journal-title":"J Inflamm Res"},{"key":"R8-20261030","doi-asserted-by":"crossref","first-page":"667875","DOI":"10.3389\/fimmu.2021.667875","article-title":"TNF-alpha pathway alternation predicts survival of immune checkpoint inhibitors in non-small cell lung cancer","volume":"12","author":"Lin","year":"2021","journal-title":"Front Immunol"},{"key":"R9-20261030","doi-asserted-by":"crossref","DOI":"10.1002\/mdr2.70001","article-title":"Systematic investigation of tumor microenvironment and antitumor immunity with IOBR","author":"Fang","year":"2025","journal-title":"Med Research"},{"key":"R11-20261030","doi-asserted-by":"crossref","first-page":"245","DOI":"10.21147\/j.issn.1000-9604.2023.03.04","article-title":"Predictive value of co-expression patterns of immune checkpoint molecules for clinical outcomes of hematological malignancies","volume":"35","author":"Chen","year":"2023","journal-title":"Chin J Cancer Res"},{"key":"R12-20261030","doi-asserted-by":"crossref","first-page":"283","DOI":"10.21147\/j.issn.1000-9604.2023.03.07","article-title":"Immune evasion and therapeutic opportunities based on natural killer cells","volume":"35","author":"Zhang","year":"2023","journal-title":"Chin J Cancer Res"},{"key":"R13-20261030","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/ijc.34332","article-title":"Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: a pharmacovigilance analysis","volume":"152","author":"Gu","year":"2023","journal-title":"Int J Cancer"},{"key":"R14-20261030","doi-asserted-by":"crossref","first-page":"102684","DOI":"10.1016\/j.eclinm.2024.102684","article-title":"Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase","volume":"73","author":"Shen","year":"2024","journal-title":"EClinicalMedicine"},{"key":"R15-20261030","doi-asserted-by":"crossref","first-page":"101967","DOI":"10.1016\/j.eclinm.2023.101967","article-title":"Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database","volume":"59","author":"Zhou","year":"2023","journal-title":"EClinicalMedicine"},{"key":"R16-20261030","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"Jco"},{"key":"R17-20261030","first-page":"25","article-title":"Rare immune-related adverse events (irAEs): approach to diagnosis and management","volume":"38","author":"Javaid","year":"2024","journal-title":"Pharmaceut Med"},{"key":"R18-20261030","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1111\/bcp.16184","article-title":"Clinical characteristics and prognosis of liver injury induced by immune checkpoint inhibitors in patients with malignancies: a real-world retrospective study","volume":"90","author":"Jiang","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"R20-20261030","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s40425-019-0604-2","article-title":"Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J Immunother Cancer"},{"key":"R21-20261030","doi-asserted-by":"crossref","first-page":"e0281983","DOI":"10.1371\/journal.pone.0281983","article-title":"Hepatotoxicity in immune checkpoint inhibitors: a pharmacovigilance study from 2014-2021","volume":"18","author":"Xu","year":"2023","journal-title":"PLoS One"},{"key":"R22-20261030","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1515\/med-2021-0267","article-title":"Fatal immune-related hepatitis with intrahepatic cholestasis and pneumonia associated with camrelizumab: a case report and literature review","volume":"16","author":"Tan","year":"2021","journal-title":"Open Med"},{"key":"R24-20261030","doi-asserted-by":"crossref","first-page":"107818","DOI":"10.1016\/j.intimp.2021.107818","article-title":"Thromboembolic events associated with immune checkpoint inhibitors: a real-world study of data from the Food and Drug Administration Adverse Event Reporting System (FAERS) database","volume":"98","author":"Li","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"R25-20261030","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"R26-20261030","doi-asserted-by":"crossref","first-page":"7451","DOI":"10.3390\/jcm12237451","article-title":"A comprehensive review of the diagnosis and management of acute liver failure","volume":"12","author":"Ozturk","year":"2023","journal-title":"J Clin Med"},{"key":"R27-20261030","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","article-title":"Visualizing and interpreting cancer genomics data via the Xena platform","volume":"38","author":"Goldman","year":"2020","journal-title":"Nat Biotechnol"},{"key":"R28-20261030","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s12064-012-0162-3","article-title":"Measurement of mRNA abundance using RNA-seq data: RPKM measure is inconsistent among samples","volume":"131","author":"Wagner","year":"2012","journal-title":"Theory in Biosciences"},{"key":"R30-20261030","doi-asserted-by":"crossref","first-page":"bbac129","DOI":"10.1093\/bib\/bbac129","article-title":"CAMOIP: a web server for comprehensive analysis on multi-omics of immunotherapy in pan-cancer","volume":"23","author":"Lin","year":"2022","journal-title":"Brief Bioinform"},{"key":"R31-20261030","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinf"},{"key":"R33-20261030","first-page":"57","article-title":"Optimization of RNA extraction from laser captured microdissected glomeruli from formalin-fixed paraffin-embedded mouse kidney samples for nanostring analysis","volume":"35","author":"Hay","year":"2020","journal-title":"Histol Histopathol"},{"key":"R34-20261030","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","article-title":"Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations","volume":"43","author":"Caster","year":"2020","journal-title":"Drug Saf"},{"key":"R35-20261030","doi-asserted-by":"crossref","first-page":"24955","DOI":"10.1038\/srep24955","article-title":"Systematic analysis of adverse event reports for sex differences in adverse drug events","volume":"6","author":"Yu","year":"2016","journal-title":"Sci Rep"},{"key":"R37-20261030","doi-asserted-by":"crossref","first-page":"101535","DOI":"10.1016\/j.eclinm.2022.101535","article-title":"Toxicity spectrum of immunotherapy in advanced lung cancer: a safety analysis from clinical trials and a pharmacovigilance system","volume":"50","author":"Yan","year":"2022","journal-title":"EClinicalMedicine"},{"key":"R38-20261030","doi-asserted-by":"crossref","first-page":"e100074","DOI":"10.1136\/egastro-2024-100074","article-title":"Bile acids regulation of cellular stress responses in liver physiology and diseases","volume":"2","author":"Li","year":"2024","journal-title":"eGastroenterology"},{"key":"R39-20261030","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.2147\/JIR.S430730","article-title":"The role of inflammation in cholestatic liver injury","volume":"16","author":"Chen","year":"2023","journal-title":"J Inflamm Res"},{"key":"R42-20261030","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13238-020-00804-9","article-title":"Targeting the alternative bile acid synthetic pathway for metabolic diseases","volume":"12","author":"Jia","year":"2021","journal-title":"Protein Cell"},{"key":"R43-20261030","doi-asserted-by":"crossref","first-page":"119367","DOI":"10.1016\/j.lfs.2021.119367","article-title":"Estrogen cholestasis induces gut and liver injury in rats involving in activating PI3K\/Akt and MAPK signaling pathways","volume":"276","author":"Xiang","year":"2021","journal-title":"Life Sci"},{"key":"R45-20261030","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.stem.2022.08.008","article-title":"Hepatic cytochrome P450 8B1 and cholic acid potentiate intestinal epithelial injury in colitis by suppressing intestinal stem cell renewal","volume":"29","author":"Chen","year":"2022","journal-title":"Cell Stem Cell"},{"key":"R47-20261030","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"R48-20261030","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41590-017-0006-x","article-title":"The twilight of immunity: emerging concepts in aging of the immune system","volume":"19","author":"Nikolich-\u017dugich","year":"2018","journal-title":"Nat Immunol"},{"key":"R49-20261030","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.3390\/ijms20112810","article-title":"The evolving role of CD8+CD28- immunosenescent T cells in cancer immunology","volume":"20","author":"Huff","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R50-20261030","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"R51-20261030","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10555-023-10097-z","article-title":"Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: the more, the better?","volume":"42","author":"Haist","year":"2023","journal-title":"Cancer Metastasis Rev"},{"key":"R52-20261030","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2023.03.003","article-title":"Combination immunotherapy for hepatocellular carcinoma","volume":"79","author":"Rimassa","year":"2023","journal-title":"J Hepatol"},{"key":"R53-20261030","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"R56-20261030","doi-asserted-by":"crossref","first-page":"815","DOI":"10.3390\/diagnostics14080815","article-title":"Risk factors for immune checkpoint inhibitor-induced liver injury and the significance of liver biopsy","volume":"14","author":"Kawano","year":"2024","journal-title":"Diagnostics"},{"key":"R57-20261030","doi-asserted-by":"crossref","first-page":"e000871","DOI":"10.1136\/jitc-2020-000871","article-title":"Impact of age on the toxicity of immune checkpoint inhibition","volume":"8","author":"Samani","year":"2020","journal-title":"J Immunother Cancer"},{"key":"R58-20261030","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejca.2020.01.013","article-title":"Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies","volume":"129","author":"Baldini","year":"2020","journal-title":"Eur J Cancer"},{"key":"R59-20261030","doi-asserted-by":"crossref","first-page":"786046","DOI":"10.3389\/fimmu.2021.786046","article-title":"Impact of patient age on clinical efficacy and toxicity of checkpoint inhibitor therapy","volume":"12","author":"Wong","year":"2021","journal-title":"Front Immunol"},{"key":"R60-20261030","doi-asserted-by":"crossref","first-page":"28309","DOI":"10.1038\/s41598-024-71746-z","article-title":"Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis","volume":"14","author":"Vitale","year":"2024","journal-title":"Sci Rep"},{"key":"R61-20261030","doi-asserted-by":"crossref","first-page":"582","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN guidelines\u00ae insights: management of immunotherapy-related toxicities, version 2.2024","volume":"22","author":"Thompson","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"R62-20261030","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/intimm\/dxl151","article-title":"Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1)","volume":"19","author":"Polanczyk","year":"2007","journal-title":"Int Immunol"},{"key":"R63-20261030","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"R64-20261030","doi-asserted-by":"crossref","first-page":"e1007622","DOI":"10.1371\/journal.pcbi.1007622","article-title":"Contrasting model mechanisms of alanine aminotransferase (ALT) release from damaged and necrotic hepatocytes as an example of general biomarker mechanisms","volume":"16","author":"Smith","year":"2020","journal-title":"PLoS Comput Biol"},{"key":"R65-20261030","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.aohep.2019.08.004","article-title":"The relative expression of hepatocellular and cholestatic liver enzymes in adult patients with liver disease","volume":"19","author":"Iluz-Freundlich","year":"2020","journal-title":"Ann Hepatol"},{"key":"R66-20261030","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.hepres.2006.01.009","article-title":"Altered expression of alkaline phosphatase (ALP) in the liver of primary biliary cirrhosis (PBC) patients","volume":"35","author":"Suzuki","year":"2006","journal-title":"Hepatol Res"},{"key":"R67-20261030","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s40265-021-01545-7","article-title":"Cholestatic liver disease: current treatment strategies and new therapeutic agents","volume":"81","author":"Hasegawa","year":"2021","journal-title":"Drugs"},{"key":"R68-20261030","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12944-023-01979-w","article-title":"Mildly elevated serum bilirubin and its correlations with lipid levels among male patients undergoing health checkups","volume":"22","author":"Bai","year":"2023","journal-title":"Lipids Health Dis"},{"key":"R70-20261030","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10637-023-01391-2","article-title":"Clinical characteristics of liver injury induced by immune checkpoint inhibitors in patients with advanced biliary tract carcinoma","volume":"41","author":"Gao","year":"2023","journal-title":"Invest New Drugs"},{"key":"R71-20261030","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1186\/s13287-021-02616-y","article-title":"Activation of the EGFR-PI3K-CaM pathway by PRL-1-overexpressing placenta-derived mesenchymal stem cells ameliorates liver cirrhosis via ER stress-dependent calcium","volume":"12","author":"Kim","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"R72-20261030","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.3390\/ph16091286","article-title":"Revisiting p38 mitogen-activated protein kinases (MAPK) in inflammatory arthritis: a narrative of the emergence of MAPK-activated protein kinase inhibitors (MK2i)","volume":"16","author":"Ganguly","year":"2023","journal-title":"Pharmaceuticals"},{"key":"R73-20261030","doi-asserted-by":"crossref","first-page":"e49255","DOI":"10.1371\/journal.pone.0049255","article-title":"ERK1\/2 and p38 MAPKs are complementarily involved in estradiol 17\u00df-D-glucuronide-induced cholestasis: crosstalk with cPKC and PI3K","volume":"7","author":"Boaglio","year":"2012","journal-title":"PLoS One"},{"key":"R74-20261030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.canlet.2016.10.008","article-title":"Targeting p38 MAP kinase signaling in cancer through post-translational modifications","volume":"384","author":"Zou","year":"2017","journal-title":"Cancer Lett"},{"key":"R75-20261030","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"R76-20261030","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.cgh.2023.02.005","article-title":"New treatment paradigms in primary biliary cholangitis","volume":"21","author":"Levy","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R77-20261030","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ctrv.2018.11.001","article-title":"Targeting the PI3K\/AKT\/mTOR pathway in biliary tract cancers: a review of current evidences and future perspectives","volume":"72","author":"Corti","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"R78-20261030","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K Pathway in Human Disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"R79-20261030","article-title":"Schaftoside alleviates HFD-induced hepatic lipid accumulation in mice via upregulating farnesoid X receptor","author":"Liu","year":"2020","journal-title":"J Ethnopharmacol"},{"key":"R80-20261030","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jhep.2020.04.033","article-title":"Danger signals in liver injury and restoration of homeostasis","volume":"73","author":"Han","year":"2020","journal-title":"J Hepatol"},{"key":"R81-20261030","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/hep.31395","article-title":"Roles of trained immunity in the pathogenesis of cholangiopathies: a therapeutic target","volume":"72","author":"Yan","year":"2020","journal-title":"Hepatology"},{"key":"R82-20261030","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3350\/cmh.2022.0327","article-title":"Taurocholic acid promotes hepatic stellate cell activation via S1PR2\/p38 MAPK\/YAP signaling under cholestatic conditions","volume":"29","author":"Yang","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"R83-20261030","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.ejso.2016.07.145","article-title":"Immunotherapy in melanoma: recent advances and future directions","volume":"43","author":"Franklin","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"R84-20261030","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s40264-016-0456-3","article-title":"Current safety concerns with human papillomavirus vaccine: a cluster analysis of reports in vigiBase\u00ae","volume":"40","author":"Chandler","year":"2017","journal-title":"Drug Saf"},{"key":"R85-20261030","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"key":"R86-20261030","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"key":"R87-20261030","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrendo.2010.235","article-title":"Adrenocortical carcinoma: a clinician\u2019s update","volume":"7","author":"Fassnacht","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"R88-20261030","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1210\/jc.2012-2851","article-title":"Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5\u03b1-reductase, explaining the need for personalized glucocorticoid and androgen replacement","volume":"98","author":"Chortis","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R89-20261030","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1186\/s12885-024-12468-3","article-title":"Monitoring immunE dysregulation foLLowing Immune checkpOint-inhibitioN (MEDALLION): protocol for an observational cancer immunotherapy cohort study","volume":"24","author":"Gault","year":"2024","journal-title":"BMC Cancer"},{"key":"R90-20261030","doi-asserted-by":"crossref","first-page":"737","DOI":"10.21037\/atm-20-5110","article-title":"The role of bile acids in cholestatic liver injury","volume":"9","author":"Cai","year":"2021","journal-title":"Ann Transl Med"},{"key":"R91-20261030","doi-asserted-by":"crossref","first-page":"746","DOI":"10.21037\/hbsn-23-319","article-title":"AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury: also useful for hepatobiliary surgeons","volume":"12","author":"Pinazo-Bandera","year":"2023","journal-title":"Hepatobiliary Surg Nutr"},{"key":"R92-20261030","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cpan.2024.12.002","article-title":"Advances in drug discovery based on network pharmacology and omics technology","volume":"21","author":"Liu","year":"2024","journal-title":"Current Pharm Anal"},{"key":"R93-20261030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cpan.2024.11.001","article-title":"Advancing pharmaceutical research: a comprehensive review of cutting-edge tools and technologies","volume":"21","author":"Chen","year":"2024","journal-title":"Current Pharm Anal"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/JS9.0000000000002607","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:01:13Z","timestamp":1793350873000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/JS9.0000000000002607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":79,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000002607","relation":{},"ISSN":["1743-9159","1743-9191"],"issn-type":[{"value":"1743-9159","type":"electronic"},{"value":"1743-9191","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"2025-02-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}